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Abstract: A key challenge for therapeutic application of RNA interference is to efﬁciently deliver
synthetic small interfering RNAs (siRNAs) into target cells that will lead to the knockdown of the
target transcript (functional siRNA delivery). To facilitate rational development of nonviral carriers,
we have investigated by imaging, pharmacological and genetic approaches the mechanisms
by which a cationic lipid carrier mediates siRNA delivery into mammalian cells. We show that
∼95% of siRNA lipoplexes enter the cells through endocytosis and persist in endolysosomes
for a prolonged period of time. However, inhibition of clathrin-, caveolin-, or lipid-raft-mediated
endocytosis or macropinocytosis fails to inhibit the knockdown of the target transcript. In contrast,
depletion of cholesterol from the plasma membrane has little effect on the cellular uptake of
siRNA lipoplexes, but it abolishes the target transcript knockdown. Furthermore, functional siRNA
delivery occurs within a few hours and is gradually inhibited by lowering temperatures. These
results demonstrate that although endocytosis is responsible for the majority of cellular uptake
of siRNA lipoplexes, a minor pathway, probably mediated by fusion between siRNA lipoplexes
and the plasma membrane, is responsible for the functional siRNA delivery. Our ﬁndings suggest
possible directions for improving functional siRNA delivery by cationic lipids.
Keywords: siRNA; delivery; cationic lipids; pathways/mechanisms
Introduction
RNA interference (RNAi) is a conserved cellular mech-
anism by which a small double stranded RNA (dsRNA)
directs the degradation of complementary mRNA and
therefore inhibits the expression of a speciﬁc gene.
1 Since
its discovery, RNAi has become a powerful tool to study
gene functions in biological processes.
2-4 The ability to
induce RNAi in mammalian cells using synthetic small
interfering RNA (siRNA) has stimulated great interest in
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5-7 In numerous studies,
siRNAs have shown promise for treating a variety of
diseases, including inﬂuenza and HIV infection, cancer and
genetic defects.
8-10
A key challenge of RNAi-based therapeutic application
is the efﬁcient delivery of siRNA into target cells. siRNA is
usually 21 nucleotides in length and highly charged and
therefore cannot cross the cytoplasmic membrane by free
diffusion. In the circulation and interstitial space, siRNA is
vulnerable to degradation by RNase.
11 Although siRNA can
be delivered directly and locally to the target sites in limited
applications,
12,13 a carrier system is required in most ap-
plications to protect siRNA from degradation and to facilitate
its uptake by target cells.
14,15 The existing carrier systems
usually contain a key cationic component, such as a cationic
lipid, a cationic polymer or a cationic peptide, in order to
bind siRNA effectively. Other supplementary components
help to improve the stability, solubility or pharmacological
proﬁles of siRNA-carrier complexes.
16
The use of carriers can dramatically increase the uptake
of siRNA. However, the efﬁcacy of the carriers in mediating
functional siRNA delivery, i.e., leading to the knockdown
of the target transcript, remains low.
17 Many of the existing
carriers were originally designed for DNA delivery, and
hence have not been optimized to account for the differences
between siRNA and DNA. The size and electrostatic charge
of siRNA are much smaller than those of DNA. siRNA
mediates its effect in the cytosol,
18 while DNA requires entry
into the nucleus in order to gain access to the transcriptional
machinery. Such differences between siRNA and DNA could
have great inﬂuences on the functionality and efﬁcacy of a
carrier.
To rationally develop efﬁcient siRNA carriers, it is
necessary to elucidate the mechanisms by which the carriers
mediate functional siRNA delivery. However, the current
knowledge on the mechanisms of the carriers comes pre-
dominantly from studies with DNA delivery. Although
different carriers have vastly different chemical structures
and physical properties, it is believed that a majority of the
DNA-carrier complexes is taken up into the cells by
endocytosis.
19,20 A primary focus in the research and
development of carriers for DNA delivery has been to
facilitate the endosomal escape of the DNA-carrier com-
plexes prior to their degradation in the lysosomes.
21,22
However, even with the most efﬁcient DNA carriers devel-
oped so far, it remains controversial to what extent the escape
from endosome contributes to transfection efﬁciency.
19-24
Considering the physical differences between siRNA and
DNA and their sites of action, whether endosomal escape
plays any signiﬁcant role in functional siRNA delivery by
the various carrier systems has yet to be determined.
In this report, we have determined the mechanisms by
which a widely used cationic lipid carrier mediates functional
delivery of siRNA by a combination of imaging, pharma-
cological and genetic approaches. We show that although
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endocytic pathways, these pathways do not appear to play a
signiﬁcant role in the delivery of siRNAs that mediate RNAi.
Instead, a novel pathway, probably mediated by direct fusion
between siRNA lipoplexes and the plasma membrane, is
responsible for the functional delivery of siRNA into the cell.
Experimental Section
Cells, siRNAs and Plasmids. African green monkey
kidney epithelial cells BSC-40, human embryonic kidney
cells 293FT, and human cervical carcinoma cells HeLa were
purchased from the American Type Culture Collection
(ATCC). The cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM), supplemented with 100 IU/mL
of penicillin, 100 IU/mL of streptomycin, 2 mM L-glutamine,
and 10% heat-inactivated fetal bovine serum (FBS) (Biowest,
Miami, FL). The cells were cultured in 6-well FALCON
tissue culture plates in a 5% CO2 humidiﬁed incubator at
37 °C.
siRNAs speciﬁc for cyclophilin B (CyB) and green
ﬂuorescent protein (GFP) and Cy5 conjugated GFP siRNA
were purchased from Dharmacon (Lafayette, CO). The
siRNA sequences are as follows: GFP siRNA: (sense) 5′-
GGCUACGUCCAGGAGCGCAdTdT-3′ and (antisense) 5′-
UGCGCUCCUGGACGUAGCCdTdT-3′.CyBsiRNA:(sense)
5′-GGAAAGACUGUUCCAAAAAdTdT-3′ and (antisense)
5′-UUUUUGGAACAGUCUUUCCdTdT-3′.
The wild-type and mutant dynamin expression plasmids
were generously provided by Dr. Mark McNiven of the Mayo
Cancer Center
25 and were cloned into pEGFP-N1 expression
vector from Clontech. The vectors expressing the wild-type
and mutant CAV-FED and CAV-DN caveolins were gener-
ously provided by Dr. Jan Eggermont
26 and were cloned into
the pCINeo/IRES-GFP expression vector. Mutant cell lines
were established by electroporation of BCS cells followed
by selection in 2.5 mg/mL Geneticin (Invitrogen, Carlsbad,
CA). The cells were maintained in 1 mg/mL Geneticin. The
day prior to experiments, the cells were sorted with a
FACSAria (Becton-Dickinson and Co.) to enrich for the GFP
positive cells. Uptake of ﬂuorescence-labeled transferrin
(Sigma-Aldrich) was used to test if the K44A mutant cells
lacked the clathrin-mediated endocytosis. Uptake of ﬂuo-
rescence-labeled cholera toxin (Invitrogen) was used to test
if the caveolin mutant cells lacked the caveolin-mediated
endocytosis.
Transfection Reagent, Lipoplex Preparation and
Transfection. DharmaFECT1, a cationic lipid based siRNA
transfection reagent, was purchased from Dharmacon.
siRNA lipoplexes were prepared following the manufactur-
er’s protocol. In brief, 4 µL of DharmaFECT1 was diluted
into 200 µL of Opti-MEM I (Invitrogen) and then mixed
with an equal volume of Opti-MEM I with appropriate
amount of siRNA. The siRNA lipoplex solution was then
diluted 5-fold in DMEM, 10% FBS for transfection. Twelve
hours prior to transfection, BSC cells were seeded in 6-well
plates at a density of 2 × 105 cells/well so that, by the time
of transfection, the cells were in the early log phase and
reached ∼70% conﬂuence. During transfection, cell culture
media were aspirated and cells were washed with PBS.
Unless otherwise speciﬁed, 2 mL of 100 nM siRNA
lipoplexes was incubated with cells for4ha t3 7°C. The
cells were subsequently washed using CellScrub buffer
(Genlantis, San Diego, CA) and PBS. After washing, fresh
media were added and cells were cultured at 37 °C for the
indicated length of time.
Inhibitors and Temperature Treatment. Pharmacologi-
cal inhibitors were purchased from Sigma-Aldrich (St. Louis,
MO) and were used at the following concentrations: cy-
tochalasin D, 100 µM; chlorpromazine, 10 µg/mL; ﬁlipin,
10 µg/mL; nystatin, 100 µg/mL; amiloride, 3 mM; D,L-threo-
1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP),
10 µM; sodium azide, 40 mM; and 2-deoxy glucose, 40 mM.
The cells were pretreated with the inhibitors for1ha t3 7
°C and then transfected with siRNA lipoplexes for4ha t3 7
°C in the presence of the inhibitors. The cells were washed
and cultured in fresh media in the absence of the inhibitors
for another 20 h prior to RNA isolation. In experiments
where siRNA transfection was carried out at 4, 10, 20, and
37 °C, the cells were incubated at speciﬁed temperatures for
1 h and then transfected with siRNA lipoplex at the same
temperatures for 4 h. The cells were washed, replenished
with fresh media, and incubated for 20 h at 37 °C prior to
RNA isolation.
RNA Extraction and Real-Time PCR Assays. At
indicated hours post-transfection, single cell suspension was
prepared and total RNA was extracted using an RNeasy mini
kit (Qiagen, Valencia, CA) according to the manufacturer’s
protocol. RNA concentration was determined by UV absor-
bance at 260 nm, and all samples had an A260/A280 ratio
greater than 1.95. The level of CyB transcript was measured
using a Real-Time PCR assay. Total RNA was ﬁrst converted
into cDNA using random hexamers and TaqMan Reverse
Transcription Reagents (Applied Biosystems, Foster City,
CA). The levels of CyB and Actin mRNAs were then
measured using TaqMan Gene Expression Assays (Applied
Biosystems). The real time RT-PCR reactions were per-
formed in Applied Biosystems’ MicroAmp optical 96-well
reaction plate, on a PRISM 7000 Real-Time PCR system.
Flow Cytometry. Cellular uptake of lipoplexes containing
DharmaFECT1 and Cy5-labeled siRNA was quantiﬁed with
ﬂow cytometry. Unless speciﬁcally indicated, 2 mL of 100
nM siRNA lipoplexes were incubated with cells for4ha t
37 °C. The cells were washed with CellScrub buffer,
trypsinized and suspended in PBS plus 2% bovine serum
albumin and 0.05% NaN3. The cells were analyzed with a
FACSCaliber and CellQuest software (Becton-Dickinson).
(25) Orth, J. D.; Krueger, E. W.; Cao, H.; McNiven, M. A. The large
GTPase dynamin regulates Actin comet formation and movement
in living cells. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 167–172.
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J. Inhibition of volume-regulated anion channels by dominant-
negative caveolin-1. Biochem. Biophys. Res. Commun. 2001, 284,
461–465.
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staining. Cellular uptake of Cy5 labeled siRNA was quanti-
ﬁed by measuring the relative ﬂuorescence signal in Cy5
channel. Cells incubated with nonlabeled siRNA lipoplexes
were used as a control, and their mean ﬂuorescence values
were subtracted from the uptake measurements of Cy5-
siRNA lipoplexes.
Fluorescence Microscopy. Cells were grown in 35 mm
diameter MatTek (MatTek, Ashland, MA) glass bottom
culture dishes, transfected with Cy5-siRNA lipoplexes, and
viewed on an inverted epiﬂuorescence microscope (Olympus
IX71, Olympus, Center Valley, PA), integrated in a Deltavi-
sion deconvolution system (Applied Precision, Issaquah,
WA). Cells were housed in an environmental chamber
(Solent Scientiﬁc, Segensworth, U.K.) to maintain constant
temperature, humidity and CO2 levels during the observation.
Unless speciﬁed, all experiments were conducted at 37 °C,
using an atmosphere of 95% air and 5% CO2. For ﬂuores-
cence imaging, cell nuclei and endolysosomes were stained
with Hoechst 33342 dye and LysoSensor Blue DND-167 dye,
respectively. Cells were viewed in Opti-MEM I medium with
an Olympus 63× PlanApo oil immersion objective with a
numerical aperture of 1.40, ﬁtted with a CoolSNAP HQ
Monochrome 12-bit cooled CCD camera (Photometrics,
Tucson, AZ). Images of 512 × 512 pixels were captured by
Applied Precision’s softWoRx software and analyzed using
Imaris 4.2 (Bitplane, Saint Paul, MN).
Statistical Method. ANOVA was used for statistical
analysis.
Results
To elucidate the mechanisms underlying the functional
siRNA delivery, we focused on DharmaFECT1, a widely
used siRNA transfection reagent based on cationic lipids.
For easy imaging analysis, we used African green monkey
kidney epithelial cells BSC-40. Human embryonic kidney
cells 293FT and human cervical carcinoma cells HeLa were
also used in certain experiments. To measure the functional
siRNA delivery, we assayed the knockdown of an endog-
enous gene cyclophilin B (CyB) because it is ubiquitously
expressed and its knockdown has no apparent effect on cell
survival and growth. CyB is also highly conserved between
human and African green monkey; therefore, the same
siRNAs are effective in cells derived from both species. We
used quantitative PCR to measure the level of CyB transcript
so as to detect the effect of functional siRNA delivery as
directly and quickly as possible. In addition, we established
that the uptake of siRNA lipoplexes is proportional to siRNA
concentration in a range of 10 pM to 200 nM, and the target
transcript knockdown is linear to siRNA concentration in a
range of 100 pM to 100 nM (Supplementary Figure S1 in
the Supporting Information). Because 100 nM siRNA
produces the most dramatic knockdown of the target
transcript but is still within the linear range, we used 100
nM siRNA in most experiments.
Majority of the siRNA Lipoplexes Persist in Endoly-
sosomes. To determine the dynamics of siRNA lipoplex
transfection, we analyzed the localization of siRNA li-
poplexes inside the cells at different times post-transfection.
BSC cells were incubated with Cy5 labeled siRNA lipoplexes
for 1, 2, or 4 h, washed and then ﬁxed for imaging analysis.
Some of the 4 h transfected cells were washed and cultured
for an additional 4, 12, and 46 h before ﬁxation and imaging
analysis. siRNA lipoplexes were detected in cells following
1 h transfection; the number of siRNA lipoplexes increased
signiﬁcantly following 4 h transfection (Figure 1A). A
signiﬁcant number of siRNA lipoplexes still persisted inside
the cells 46 h post-transfection.
The punctate pattern of intracellular siRNA lipoplexes
suggests that they localize in endolysosomes. Thus, cells were
stained with LysoSensor speciﬁc for endolysosomes and then
transfected with siRNA lipoplexes for 1, 2, 3, and 4 h.
Quantiﬁcation of colocalization of LysoSensor and Cy5-
labeled siRNA lipoplexes revealed that >90% siRNA li-
poplexes were localized in the endolysosomes (Figure 1B).
To determine the relationship between the observed uptake
of siRNA lipoplexes and the target transcript knockdown,
BSC cells were transfected for either 2 or 4 h and assayed
for CyB transcript level immediately, or transfected for 4 h,
washed and cultured for additional 2 or 20 h before
measuring the level of CyB transcript. A decrease in CyB
mRNA level was detected following 2 h transfection, but a
signiﬁcant decrease was clearly evident following 4 h
transfection (Figure 1C). Additional culture of 4 h transfected
cells resulted in further decrease of CyB transcript level. By
comparing Figures 1A, 1B and 1C, it is clear that signiﬁcant
target mRNA knockdown occurred in the absence of
signiﬁcant change in the level of siRNA lipoplexes in the
endolysomes. Becausea4hsiRNA lipoplex transfection
followed by a 20 h culture results in a consistent CyB mRNA
knockdown by 80-90%, we used this assay format in the
rest of the study.
Functional siRNA Delivery Is Independent of the
Clathrin-Mediated Endocytosis. One of the best character-
ized and most important endocytosis pathways is the clathrin-
mediated endocytosis, which is responsible for the uptake
of a wide variety of macromolecules from extracellular
environment.
27 To quantify the uptake of siRNA lipoplexes
through this pathway, BSC cells were treated with chlor-
promazine or cytochalasin D, which inhibit clathrin-mediated
endocytosis,
28 followed by siRNA lipoplex transfection.
After washing, uptake of siRNA lipoplexes was measured
by microscopy and ﬂow cytometry. CyB transcript level was
measured following 20 h culture. Both inhibitors reduced
the uptake of Cy5 labeled siRNA lipoplexes by ∼50%
(27) Dautry-Varsat, A. Receptor-mediated endocytosis: the intracellular
journey of transferrin and its receptor. Biochimie 1986, 68, 375–
381.
(28) Subtil, A.; Hemar, A.; Dautry-Varsat, A. Rapid endocytosis of
interleukin 2 receptors when clathrin-coated pit endocytosis is
inhibited. J. Cell Sci. 1994, 107, 3461–3468.
articles Lu et al.
766 MOLECULAR PHARMACEUTICS VOL. 6, NO. 3(Figure 2A and Supplementary Figure S2A in the Supporting
Information). However, siRNA mediated knockdown of CyB
transcript was not diminished in the presence of these
inhibitors (Figure 2B).
Dynamin is required for the clathrin-mediated endo-
cytosis.
29,30 To conﬁrm the results with pharmacological
inhibitors, we constructed BSC cells that constitutively
expressed the wild-type or a dominant-negative form of
dynamin with mutation of lysine at the position 44 to
alanine (termed K44A).
29 Expression of the mutant but
not the wild-type dynamin inhibited the uptake of trans-
ferrin (Supplementary Figure S2B in the Supporting
Information), a marker for the clathrin-mediated endocy-
tosis. However, siRNA-mediated knockdown of the target
transcript was not affected by expression of either the
wild-type or K44A dynamin (Figure 2C). Similarly,
transient expression of K44A dynamin in human embry-
(29) van der Bliek, A. M.; Redelmeier, T. E.; Damke, H.; Tisdale,
E. J.; Meyerowitz, E. M.; Schmid, S. L. Mutations in human
dynamin block an intermediate stage in coated vesicle formation.
J. Cell Biol. 1993, 122, 553–563.
(30) Herskovits, J. S.; Burgess, C. C.; Obar, R. A.; Vallee, R. B. Effects
of mutant rat dynamin on endocytosis. J. Cell Biol. 1993, 122,
565–578.
Figure 1. Uptake of the bulk of siRNA lipoplexes and
functional siRNA delivery are not correlated. (A)
Imaging analysis of siRNA lipoplexes inside the cells.
Cy5-siRNA lipoplexes were incubated with BSC cells for
the indicated length of time, washed, and cultured for
the indicated length of time before ﬁxation and imaging
analysis. Cy5-siRNA lipoplexes were red and nuclei
were stained blue. Representative images at the
indicated times are shown. Scale bar, 10 µm. (B) siRNA
lipoplexes colocalize with endolysosomes. BSC cells
were transfected with Cy5-siRNA lipoplexes for the
indicated length of time in the presence of LysoSensor.
Live cell imaging was carried out at different time points
after transfection. The number of intracellular siRNA
complexes and the number of siRNA complexes that
overlapped with LysoSensor staining were enumerated.
Percentages of intracellular siRNA complexes that
colocalize with LysoSensor are shown at the indicated
time points. (C) Kinetics of target mRNA knockdown.
BSC cells were transfected with CyB-speciﬁc siRNA
lipoplexes for 2 or 4 h, washed, were used for RNA
isolation immediately. Some 4 h transfected cells were
cultured for another 2 or 20 h before RNA isolation. The
levels of CyB transcript were quantiﬁed by real-time
PCR and normalized to that in nontransfected cells.
Percentages of target mRNA level are shown as mean
( SD. P values between selected samples are
indicated. Representative data from one of three to ﬁve
experiments are shown.
Figure 2. Inhibition of clathrin-mediated endocytosis
signiﬁcantly blocks uptake of siRNA lipoplexes but not
functional siRNA delivery. BSC cells were treated with
chlorpromazine (Chlorp, 10 µg/mL) or cytochalasin D
(CytoD, 100 µM) for 1 h followed by siRNA lipoplex
transfection for4hi nt h epresence of the inhibitors.
After washing, siRNA lipoplex uptake was measured by
ﬂow cytometry (see Experimental Section for details).
Transfected cells were cultured for another 20 h before
CyB transcript level was measured by real-time PCR.
(A) Uptake of Cy5-siRNA lipoplexes in the absence or
presence of inhibitors. (B) Relative levels of CyB
transcript in the presence or absence of inhibitors as
normalized to the level of untreated cells. (C) Relative
levels of CyB transcript in BSC cells that expressed the
wild-type (WT) or K44A dynamin. BSC cells that stably
express either the WT or K44A dynamin were
transfected with siRNA lipoplexes for 4 h, washed,
cultured for 20 h, and then assayed for CyB transcript
level. Data shown are mean ( SD (n ) 4).
Representative data from one of three to ﬁve experi-
ments are shown.
Mechanisms of Cationic Lipid-Mediated siRNA DeliVery articles
VOL. 6, NO. 3 MOLECULAR PHARMACEUTICS 767onic kidney cells 293FT did not inhibit the knockdown
of target transcript following siRNA lipoplex transfection
(Supplementary Figure S2C in the Supporting Informa-
tion). Inducible expression of K44A dynamin in human
cervical carcinoma cells HeLa also did not affect target
transcript knockdown (Supplementary Figure S2D in the
Supporting Information). Together, these results show that
although the clathrin-mediated endocytosis is a major
pathway for cellular uptake of siRNA lipoplexes, it does
not appear to contribute signiﬁcantly to the functional
siRNA delivery.
Functional Delivery of siRNA Lipoplexes Is Sensitive
to Cholesterol Depletion. Next, we determined if functional
siRNA delivery is dependent on cholesterol because cho-
lesterol is a critical component of the cytoplasmic membrane
and plays a critical role in many membrane-associated events,
including membrane fusion, macropinocytosis, and caveolin-
and lipid-raft-mediated endocytosis.
31,32 BSC cells were
treated with nystatin or ﬁlipin for1ht odeplete cholesterol
from the plasma membrane
33,34 and then transfected with
siRNA lipoplexes for4hi nt h epresence of the inhibitors.
After washing, cells were assayed for siRNA lipoplex uptake
by ﬂow cytometery or cultured for 20 h and then assayed
for CyB transcript level. Under these conditions, cytotoxicity
was minimal because >90% of the cells did not take up
propidium iodide. As shown in Figure 3, although treating
cells with nystatin or ﬁlipin had minimal effect on the uptake
of siRNA lipoplexes, target mRNA knockdown was com-
pletely abolished in the presence of ﬁlipin and signiﬁcantly
reduced in the presence of nystatin. To exclude the possibility
that the inhibitors may have interfered with the functional
siRNA delivery by destabilizing the siRNA lipoplexes, we
measured the particle size of siRNA lipoplexes in the
presence of the inhibitors by dynamic light scattering. When
the inhibitors were added to siRNA lipoplexes, the size of
the particles remained the same, with >95% of the particles
were 100-200 nm in diameter (data not shown). In addition,
after the inhibitors were removed from the siRNA lipoplexes
suspension by dialysis, the siRNA lipoplexes remained active
and mediated efﬁcient RNAi (Supplementary Figure S3 in
the Supporting Information). Hence, depletion of cholesterol
from the plasma membrane abolishes functional delivery of
siRNA mediated by cationic lipids.
Functional Delivery of siRNA Lipoplexes Does Not
Depend on Macropinocytosis or Caveolin- or Lipid-Raft-
Mediated Endocytosis. Among the various endocytic path-
ways that are sensitive to cholesterol depletion, the caveolin-
mediated endocytosis is perhaps the best characterized.
35,36
To determine whether this pathway contributes to the
functional delivery of siRNA by cationic lipids, we con-
structed BSC cells that stably expressed one of the two
dominant-negative caveolin constructs: One mutant, termed
CAV-DN, harbored a deletion of amino acid residues 1-81
at the N-terminal; and the other mutant, termed CAV-FED,
had amino acid residues 68-73 replaced with AAAAAG.
26
Expression of the mutant but not the wild-type caveolin in
BSC cells resulted in the inhibition of the uptake of cholera
toxin (Supplementary Figure S4A in the Supporting Informa-
tion), suggesting that caveolin-mediated endocytosis is
inhibited signiﬁcantly. However, transfection of siRNA
lipoplexes into BSC cells expressing either the wild-type or
the mutant caveolin resulted in CyB knockdown to the same
extent (Figure 4A). Similarly, transient expression of the
dominant negative caveolins in 293FT cells did not diminish
CyB transcript knockdown (Supplementary Figure S4B in
the Supporting Information).
D,L-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-pro-
panol (PDMP) inhibits synthesis of sphingolipid,
37 a com-
(31) Umeda, M.; Nojima, S.; Inoue, K. Effect of lipid composition on
HVJ-mediated fusion of glycophorin liposomes to erythrocytes.
J. Biochem. 1985, 97, 1301–1310.
(32) Grimmer, S.; van Deurs, B.; Sandvig, K. Membrane rufﬂing and
macropinocytosis in A431 cells require cholesterol. J. Cell Sci.
2002, 115, 2953–2962.
(33) Ushio-Fukai, M.; Hilenski, L.; Santanam, N.; Becker, P. L.; Ma,
Y.; Griendling, K. K.; Alexander, R. W. Cholesterol depletion
inhibits epidermal growth factor receptor transactivation by
angiotensin II in vascular smooth muscle cells: role of cholesterol-
rich microdomains and focal adhesions in angiotensin II signaling.
J. Biol. Chem. 2001, 276, 48269–48275.
(34) Rothberg, K. G.; Ying, Y. S.; Kamen, B. A.; Anderson, R. G.
Cholesterol controls the clustering of the glycophospholipid-
anchored membrane receptor for 5-methyltetrahydrofolate. J. Cell
Biol. 1990, 111, 2931–2938.
(35) Nichols, B. Caveosomes and endocytosis of lipid rafts. J. Cell
Sci. 2003, 116, 4707–4714.
(36) Parton, R. G.; Richards, A. A. Lipid rafts and caveolae as portals
for endocytosis: new insights and common mechanisms. Trafﬁc
2003, 4, 724–738.
(37) Kobayashi, T.; Takahashi, M.; Nagatsuka, Y.; Hirabayashi, Y.
Lipid rafts: new tools and a new component. Biol. Pharm. Bull.
2006, 29, 1526–1531.
Figure 3. Cholesterol depletion inhibits functional
siRNA delivery. (A) Uptake of siRNA lipoplexes in the
absence or presence of either nystatin (100 µg/mL)
or ﬁlipin (10 µg/mL) as measured by ﬂow cytometry.
(B) Relative CyB transcript level in the presence or
absence of the inhibitors. Representative data are
shown as mean ( SD (n ) 4). P values between
selected samples are shown. Representative data
from one of three experiments are shown.
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38 Treatment of BSC
cells with PDMP had no effect on knockdown of target
transcript following transfection with siRNA lipoplexes
(Figure 4B) although it inhibited the uptake of siRNA
lipoplexes by approximately 20% (Figure 4D). Similarly,
amiloride, a strong inhibitor of macropinocytosis,
39 showed
no signiﬁcant effect on either the knockdown of CyB
transcript or siRNA lipoplex uptake (Figure 4C,D). Together,
these results suggest that functional delivery of siRNA
lipoplexes does not appear to depend on caveolin- or lipid-
raft-mediated endocytosis or macropinocytosis.
Functional Delivery of siRNA Lipoplexes Is Tempera-
ture Sensitive. To determine if the functional delivery of
siRNA lipoplexes is an energy-dependent process, we treated
the cells with deoxy-glucose and sodium azide to inhibit ATP
biosynthesis. BSC cells were treated with both inhibitors for
1 h and then transfected with siRNA lipoplexes for4hi n
the presence of the inhibitors. After washing, cells were
assayed immediately for siRNA uptake or cultured for 20 h
in the absence of the inhibitors (to avoid inhibition of RNAi
reaction) and then assayed for CyB transcript level. The
treatment inhibited the uptake of siRNA lipoplexes by ∼70%
(Figure 5A). However, inhibition of ATP biosynthesis during
transfection did not diminish the target transcript knockdown
(Figure 5B), suggesting that the functional delivery of siRNA
lipoplexes does not appear to depend on new ATP
biosynthesis.
We examined the effect of temperature on functional
delivery of siRNA lipoplexes. BSC cells were precooled to
4, 10, or 20 °C for 1 h and then transfected with siRNA
lipoplexes for4ha tt h esame temperatures. After washing,
the cells were incubated at 37 °C for 20 h and assayed for
CyB transcript level. Knockdown of the target transcript was
signiﬁcantly reduced at low temperatures (Figure 5C). Curve
ﬁtting suggests that the reduction of target transcript level
was exponential (no sharp transition) as temperature de-
creases, suggesting that the effect of temperature on func-
tional delivery of siRNA lipoplexes is gradual.
Discussion
In this study, we examined pathways by which siRNA
lipoplexes are taken up by cells to determine whether speciﬁc
uptake pathways contribute to functional siRNA delivery.
Our results show that ∼95% of siRNA lipoplexes that enter
cells end up in the endolysosomes, most of which are
contributed by clathrin-mediated endocytosis (∼50%) and
lipid-raft-mediated endocytosis (∼20%). These ﬁndings are
consistent with observations that endocytosis is the major
(38) Sillence, D. J. New insights into glycosphingolipid functionss
storage, lipid rafts, and translocators. Int. ReV. Cytol. 2007, 262,
151–189.
(39) von Delwig, A.; Hilkens, C. M.; Altmann, D. M.; Holmdahl, R.;
Isaacs, J. D.; Harding, C. V.; Robertson, H.; McKie, N.; Robinson,
J. H. Inhibition of macropinocytosis blocks antigen presentation
of type II collagen in vitro and in vivo in HLA-DR1 transgenic
mice. Arthritis Res. Ther. 2006, 8, R93.
Figure 4. Functional delivery of siRNA lipoplexes is not
dependent on caveolin- or lipid-raft-mediated endocytosis
or macropinocytosis. (A) Relative levels of CyB transcript
in BSC cells that express the wild-type (WT) or the mutant
caveolins. BSC cells that stably expressed either the
wild-type or one of the mutant caveolins were transfected
with siRNA lipoplexes for 4 h, washed and cultured for
20 h. The level of CyB transcript was quantiﬁed. (B, C)
Effect of PDMP (B) or amiloride (C) on functional siRNA
delivery. BSC cells were treated with PDMP (10 µM) or
amiloride (3 mM) for 1 h, followed by siRNA lipoplex
transfection for 4 h, washed, and cultured for 20 h. The
level of CyB transcript was quantiﬁed. (D) Uptake of Cy5
labeled siRNA lipoplexes in the absence or presence of
inhibitors as quantiﬁed by ﬂow cytometry. Representative
data are shown as mean ( SD (n ) 4). P values between
selected samples are shown. Representative data from
one of three experiments are shown.
Figure 5. Effect of lowing temperature and inhibiting ATP
biosynthesis on functional delivery of siRNA lipoplexes. (A)
Uptake of siRNA lipoplexes in the absence or presence of
deoxy-glucose (40 mM) and sodium azide (40 mM). (B)
Relative level of CyB transcript in the presence or
absence of ATP biosynthesis inhibitors. (C) Effect of
temperature on knockdown of target transcript. Represen-
tative data are shown as mean ( SD (n ) 3o r4 ) .R2
value of exponential ﬁt is shown. Representative data from
one of three experiments are shown.
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20,22-24,40,41
Despite the contribution to the uptake of the majority of
siRNA lipoplexes, the endocytotic pathways do not appear
to contribute signiﬁcantly to functional siRNA delivery as
measured by target transcript knockdown. Consistent with
this observation, while endocytosis is an energy-dependent
process,
27,32 functional siRNA delivery mediated by cationic
lipids is independent of new ATP biosynthesis during the
transfection period. Furthermore, inhibition of clathrin-
mediated endocytosis by either pharmacological inhibitors
or expression of a dominant negative dynamin did not inhibit
the knockdown of the target transcript (Figure 2). Similarly,
inhibition of caveolin-mediated endocytosis, lipid-raft-medi-
ated endocytosis or macropinocytosis did not diminish the
knockdown of the target transcript (Figure 4). While these
results do not exclude the possibility that a small amount of
siRNA lipoplexes “leaked” out of endolysosomes following
endocytosis and contributed to the target gene silencing,
taking together, they suggest alternative mechanisms of
cationic lipid-mediated functional siRNA delivery.
The functional delivery of siRNA mediated by cationic
lipids is shown here to be a rapid process as inferred from
the rapid knockdown of target transcript (Figure 1C).
Furthermore, the process is temperature sensitive but does
not require new ATP biosynthesis during the transfection
period (Figure 5). Based on these characteristics, the mech-
anism underlying the cationic lipid-mediated functional
siRNA delivery is probably through direct fusion between
siRNA lipoplexes and the plasma membrane. Membrane
fusion requires cholesterol,
31 and it is notable that depletion
of cholesterol from the plasma membrane by treating cells
with nystain or ﬁlipin abolished or signiﬁcantly inhibited
target transcript knockdown (Figure 3). Because treating cells
with nystain or ﬁlipin did not signiﬁcantly inhibit the bulk
uptake of siRNA lipoplexes, the functional siRNA delivery
likely occurs through a minor uptake pathway, consistent
with the mechanism of a direct fusion.
The mechanisms by which cationic lipids mediate DNA
delivery have been investigated extensively.
19,21,23,24,40-44
During cationic lipid-mediated DNA delivery, the lipids
function by compacting plasmid DNA into DNA-containing
liposomes or lipid-DNA complexes (lipoplexes). The li-
poplexes facilitate cellular uptake of DNA primarily via
endocytosis following binding of positively charged lipid-
DNA lipoplexes to the negatively charged cellular sur-
faces.
19,23,24,43 Although fusion of DNA lipoplexes with the
plasma membrane was initially suggested as a way to deliver
DNA directly into the cytoplasm,
19 lipid mixing assays did
not reveal a correlation between fusion of DNA lipoplexes
withplasmamembranesandtheirtransfectionefﬁciency.
41,45-47
Rather, it seems that when DNA lipoplexes fuse with the
cellular membrane, DNA tends to be excluded at the cell
surface and does not enter the cell.
48 Because the majority
of DNA lipoplexes end up in the endolysosomes, most of
the effort to enhance DNA transfection has focused on
stimulating the escape of DNA lipoplexes from the
endolysosomes.
What could account for the differences in the mechanisms
of cationic lipid mediated siRNA and DNA delivery? Both
DNA and siRNA are negatively charged. This similarity
could account for the uptake of siRNA or DNA lipoplexes
by the same endocytosis pathways. However, siRNA is much
smaller than DNA and functions in the cytosol whereas DNA
has to be transported into the nucleus to be transcribed. Upon
fusion of siRNA lipoplexes with the plasma membrane, some
siRNA is likely delivered directly into the cytosol, where
siRNA can be readily recruited into RNAi mechinary to exert
its effect. In contrast, DNA delivered into the cytosol via
fusion has to be transported into nucleus before it can be
transcribed. Even if some DNA is delivered directly into the
cytosol, it may not contribute signiﬁcantly to the functional
DNA delivery. This difference could potentially account for
the different mechanisms by which cationic lipids mediate
functional siRNA versus DNA delivery. Thus, one practical
signiﬁcance of our observations is that optimizing conditions
for fusion between siRNA lipoplexes and the plasma
membrane should improve functional siRNA delivery by
cationic lipids.
In summary, our studies show that although most siRNA
lipoplexes enter cells via endocytosis, this mode of entry
does not appear to contribute signiﬁcantly to functional
siRNA delivery. Instead, a minor but rapid pathway, probably
mediated by fusion of siRNA lipoplexes with the plasma
membrane, accounts for the ﬁnding that only a small fraction
of the siRNA lipoplexes that enter cells are responsible for
most of the observed siRNA-mediated target gene knockdown. (40) Zuhorn, I. S.; Kalicharan, R.; Hoekstra, D. Lipoplex-mediated
transfection of mammalian cells occurs through the cholesterol-
dependent clathrin-mediated pathway of endocytosis. J. Biol.
Chem. 2002, 277, 18021–18028.
(41) Zhou, X.; Huang, L. DNA transfection mediated by cationic
liposomes containing lipopolylysine: characterization and mech-
anism of action. Biochim. Biophys. Acta 1994, 1189, 195–203.
(42) Friend, D. S.; Papahadjopoulos, D.; Debs, R. J. Endocytosis and
intracellular processing accompanying transfection mediated by
cationic liposomes. Biochim. Biophys. Acta 1996, 1278, 41–50.
(43) Gao, X.; Huang, L. Cationic liposome-mediated gene transfer.
Gene Ther. 1995, 2, 710–722.
(44) Kawaura, C.; Noguchi, A.; Furuno, T.; Nakanishi, M. Atomic force
microscopy for studying gene transfection mediated by cationic
liposomes with a cationic cholesterol derivative. FEBS Lett. 1998,
421, 69–72.
(45) Oberle, V.; Bakowsky, U.; Zuhorn, I. S.; Hoekstra, D. Lipoplex
formation under equilibrium conditions reveals a three-step
mechanism. Biophys. J. 2000, 79, 1447–1454.
(46) Pires, P.; Simo ˜es, S.; Nir, S.; Gaspar, R.; Du ¨zgu ¨nes, N.; Pedroso
de Lima, M. C. Interaction of cationic liposomes and their DNA
complexes with monocytic leukemia cells. Biochim. Biophys. Acta
1999, 1418, 71–84.
(47) Stegmann, T.; Legendre, J. Y. Gene transfer mediated by cationic
lipids: lack of a correlation between lipid mixing and transfection.
Biochim. Biophys. Acta 1997, 1325, 71–79.
(48) Elouahabi, A.; Thiry, M.; Pector, V.; Ruysschaert, J. M.; Van-
denbranden, M. Calorimetry of cationic liposome-DNA complex
and intracellular visualization of the complexes. Methods Enzymol.
2003, 373, 313–332.
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